Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 3/20 | 0.37 |
| ▸ | GIPR | P48546 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195752 | 0.89 | APEX1 (0.46) | APEX1GAAMEN1KMT2ACYP3A4 | |
| SCHEMBL4184834 | 0.85 | GCGR (0.39) | GAAMEN1KMT2ACYP3A4TP53 | |
| SCHEMBL4186907 | 0.85 | CA12 (0.50) | APEX1GAAMEN1KMT2ACYP3A4 | |
| SCHEMBL13653122 | 0.84 | GCGR (0.37) | MEN1KMT2AGCGRGIPR | |
| SCHEMBL4195612 | 0.81 | CA12 (0.45) | APEX1MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4174953 | 0.80 | CA12 (0.50) | APEX1GAATP53ALDH1A1MAPT | |
| SCHEMBL4185822 | 0.79 | HDAC1 (0.50) | MAPTTAS2R14 | |
| SCHEMBL13653112 | 0.79 | GCGR (0.40) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4187089 | 0.79 | CA12 (0.49) | GAAALDH1A1LMNA | |
| SCHEMBL4197907 | 0.79 | HDAC1 (0.45) | MEN1KMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247590-A1 | Indane amides | MKI67, PPIP5K2, CCNA1 | APEX1 732/4885GAA 1331/4885MEN1 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.